Godlike Productions - Discussion Forum
Users Online Now: 2,003 (Who's On?)Visitors Today: 461,872
Pageviews Today: 780,292Threads Today: 332Posts Today: 5,074
10:10 AM


Back to Forum
Back to Forum
Back to Thread
Back to Thread
REPLY TO THREAD
Subject Created in Russia, the cure for hepatitis D received the status of "breakthrough therapy" in the United States
User Name
 
 
Font color:  Font:








In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 50% of the source material, provide a link back to the original article and provide your original comments / criticism in your post with the article.
Original Message This drug will appear on the Russian market at the end of 2019. MOSCOW, December 17. / TASS /. The world's first drug from previously incurable hepatitis D, created by a resident of the Skolkovo Foundation by the biotechnology company Hepatera, received the status of “breakthrough therapy” from the US Food and Drug Administration (FDA). This was reported on Monday by the press service of the fund.

“The drug Myrcludex B, created by the resident of the Skolkovo Foundation by the biotechnological company Hepatera, received the status of“ breakthrough therapy ”from the US Food and Drug Administration (FDA). Myrcludex B is the world's first medicine for previously incurable hepatitis D. It is also effective for treating hepatitis B, ”the report says.
Getting the status of "breakthrough therapy" from the FDA means that international experts in the field of drug development and testing confirm the effectiveness of the drug.
In the future, it will simplify the delivery of drugs to the markets of the United States and Europe. It is noted that the effectiveness and safety of the drug was proven during research in leading clinics in Russia and Germany. This drug will appear on the Russian market at the end of 2019.

Myrcludex B was created on the basis of research by scientists from the University of Ruprecht and Karl (Ruprecht-Karls-Universitt Heidelberg) and is being developed in the framework of international cooperation with the biotechnology company MYR Pharma, GmbH (Germany). Myrcludex B blocks the receptor through which viral particles penetrate the liver cells. As a result, the further spread of inflammation and the development of dangerous complications are prevented. When protein is blocked, viruses remain outside the cells, where they are destroyed by the body’s immune system.
Hepatera is developing a first-class drug for the treatment of chronic hepatitis B with a delta agent - the most severe viral liver disease, affecting about 15 million people worldwide. To date, there is no registered standard therapy in 90% of patients, and in 10% of patients there is an extremely low efficacy of treatment with a single prescribed drug, pegylated interferon (PEG-IFN)
Camila Zarubina
Director of Acceleration, Cluster of Biological and Medical Technologies of the Skolkovo FoundationThe World Health Organization estimates that around 257 million people in the world now have hepatitis B.

About 15 million of them are infected with hepatitis D (develops only when hepatitis B is present). Patients infected with hepatitis D have a high probability of developing a terminal stage of liver failure as a result of an acute infection, rapid development of cirrhosis of the liver, and in the case of chronic infections, the likelihood of hepatocellular carcinoma (liver cancer). Every year, acute viral hepatitis takes almost half a million lives - more than HIV infection, malaria and tuberculosis.
[link to news.mail.ru (secure)]
Pictures (click to insert)
5ahidingiamwithranttomatowtf
bsflagIdol1hfbumpyodayeahsure
banana2burnitafros226rockonredface
pigchefabductwhateverpeacecool2tounge
 | Next Page >>





GLP